Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease

Condition(s) studied

Investigational drug(s) / intervention(s)

Antihypertensive algorithm: Antihypertensive algorithm based on diuretics agents

Standard of care: standard of care management for antihypertensive therapy intensification

Study summary

Chronic kidney disease (CKD) is a major public health issue worldwide. Hypertension is the first risk factor in patients with CKD for mortality, cardiovascular disease and end-stage renal disease. It's now well established that lowering blood pressure (BP) reduces renal and cardiovascular complications in this high-risk population. In the general population, in addition to lifestyle interventions, the strategy to initiate and escalate a BP-lowering drug treatment is well described. The drug therapies recommended to achieve optimal BP control in the general population are the following: blockers of the renin-angiotensin system (angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)), diuretics (thiazides and thiazide-like diuretics), and calcium channel blockers. For patients with CKD, the guidelines advise to start the BP-lowering agent with ACEi or ARB, but then, there is no strong evidence to support the preferential use of any particular agent in controlling BP and the results of clinical trials are discordant. In the NephroTest cohort, a French cohort of patients with CKD stage 1 to 5, among 2015 patients, 1782 had hypertension, only 54% had a diuretic and 44% had uncontrolled hypertension. In this cohort, extracellular fluid (ECF) overload was an independent determinant of hypertension, uncontrolled hypertension and apparent treatment resistant hypertension. In the same cohort, ECF overload was independently associated with end-stage kidney disease and death. Our hypothesis is that patients with CKD and uncontrolled hypertension are fluid overloaded and that the second line of treatment after an ACEi or an ARB should be a diuretic. We hypothesize that a specific algorithm to lower BP in patients with moderate to severe CKD based on diuretics will be more effective in term of cardiovascular event, mortality and evolution to end-stage kidney disease as compared to standard of care.

Eligibility

Primary outcome measure(s)

• End stage kidney disease — Up to 36 months
  The primary endpoint is a time to event outcome, considering the following composite endpoint: * End stage kidney disease * eGFR decline of at least 40% * Cardiovascular events among myocardial infarction, heart failure, hospitalization and stroke * All cause mortality
• eGFR decline of at least 40% — Up to 36 months
  The primary endpoint is a time to event outcome, considering the following composite endpoint: * End stage kidney disease * eGFR decline of at least 40% * Cardiovascular events among myocardial infarction, heart failure, hospitalization and stroke * All cause mortality
• Cardiovascular events — Up to 36 months
  The primary endpoint is a time to event outcome, considering the following composite endpoint: * End stage kidney disease * eGFR decline of at least 40% * Cardiovascular events among myocardial infarction, heart failure, hospitalization and stroke * All cause mortality
• All cause mortality — Up to 36 months
  The primary endpoint is a time to event outcome, considering the following composite endpoint: * End stage kidney disease * eGFR decline of at least 40% * Cardiovascular events among myocardial infarction, heart failure, hospitalization and stroke * All cause mortality

Trial sites (40)

More University Hospital, Tours trials in France

Other trials for the same condition